Feb 25, 2021 / 03:45PM GMT
Joanne Karen Wuensch - Citigroup Inc. Exchange Research - Research Analyst
Hello, everybody. Thank you for rejoining us. I'm thrilled today that we have moved on to talk about Johnson & Johnson. And we have Jennifer Taubert with us, EVP, Worldwide Chairman of Pharmaceuticals. Jennifer, welcome.
Jennifer L. Taubert - Johnson & Johnson - Executive VP & Worldwide Chairman of Pharmaceuticals
Thank you so much, Joanne. I'm really happy to be here with you today, and hello, everybody. First of all, on behalf of J&J, I hope that you and your families are remaining safe and healthy. I'm really proud to have a chance to chat with you today around -- about our Pharmaceutical business, which delivered really robust, very, very strong growth throughout 2020, exceeding the market growth rates for our ninth consecutive year.
A couple -- few things I'd like to run through with you here today. First, our broadly based growth was across regions, it was across therapeutic areas, and it was across our key brands. And we think that, that's a key indication
Johnson & Johnson at Citi Healthcare Services, Medtech, Tools, & HCIT Virtual Conference Transcript
Feb 25, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers